文献速递心力衰竭与心肌病

瞬时细胞周期诱导心肌细胞治疗亚急性缺血性心力衰竭

Transient Cell Cycle Induction in Cardiomyocytes to Treat Subacute Ischemic Heart Failure.
PubMed 文献 · Circulation · 2022-01-21

本研究通过时序单细胞RNA测序揭示4种细胞周期因子(4F)强制心肌细胞增殖的重编程阶段,并在大鼠和猪缺血性心衰模型中首次开展临床前测试。结果显示,心肌细胞特异性瞬时表达4F可显著改善左室射血分数和瘢痕大小,且4个月后大鼠心功能持续改善,未见明显心律失常或全身肿瘤发生。

要点

  • 4F基因治疗在缺血性心衰动物模型中改善心功能和瘢痕大小。
  • 心肌细胞特异性瞬时表达4F可降低致癌风险,提高临床可行性。
  • 4个月随访大鼠心功能持续改善,未观察到明显心律失常或肿瘤。

核心结论

  • 心肌细胞特异性瞬时表达4F基因治疗可改善缺血性心衰动物模型的心功能和瘢痕大小。

研究设计与样本

  • 使用时序单细胞RNA测序鉴定4F强制心肌细胞增殖的重编程阶段。
  • 在大鼠和猪缺血性心衰模型中开展临床前测试,通过多顺反子非整合慢病毒载体递送4F。
  • 大鼠心肌梗死后1周心肌内注射TNNT2-4Fpolycistronic-NIL或对照病毒(n=10/组),猪模型(n=6-7/组)。

主要发现

  • 4F感染后48小时,15%的心肌细胞群体发生完全细胞周期重编程,主要与肌节解体和代谢重编程相关(n=3/时间点/组)。
  • 注射后4周,TNNT2-4Fpolycistronic-NIL治疗组动物左室射血分数和瘢痕大小较对照病毒组显著改善。
  • 治疗4个月后,大鼠心功能持续改善,未见明显心律失常或全身肿瘤发生(n=10/组)。

关键数值与推荐

  • 4F包括CDK1、CDK4、CCNB和CCND。
  • 体外实验中使用LacZ或4F腺病毒感染成熟人诱导多能干细胞衍生心肌细胞。
  • TNNT2-4Fpolycistronic-NIL为多顺反子非整合慢病毒,每个因子由TNNT2启动子驱动。

临床怎么用

  • 该研究为缺血性心衰的基因治疗提供了临床前证据,支持进一步开展临床试验。
  • 心肌细胞特异性瞬时表达4F策略可能降低全身肿瘤风险,但需在人体中验证安全性和有效性。

局限性

  • 研究仅在大鼠和猪模型中进行,尚未在人体中验证。
  • 样本量较小(大鼠n=10/组,猪n=6-7/组),需更大规模研究确认。
  • 长期安全性(如心律失常和肿瘤发生)仅在 rats 中观察至4个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The regenerative capacity of the heart after myocardial infarction is limited. Our previous study showed that ectopic introduction of 4 cell cycle factors (4F; CDK1 [cyclin-dependent kinase 1], CDK4 [cyclin-dependent kinase 4], CCNB [cyclin B1], and CCND [cyclin D1]) promotes cardiomyocyte proliferation in 15% to 20% of infected cardiomyocytes in vitro and in vivo and improves cardiac function after myocardial infarction in mice. METHODS: Using temporal single-cell RNA sequencing, we aimed to identify the necessary reprogramming stages during the forced cardiomyocyte proliferation with 4F on a single cell basis. Using rat and pig models of ischemic heart failure, we aimed to start the first preclinical testing to introduce 4F gene therapy as a candidate for the treatment of ischemia-induced heart failure. RESULTS: Temporal bulk and single-cell RNA sequencing and further biochemical validations of mature human induced pluripotent stem cell-derived cardiomyocytes treated with either LacZ or 4F adenoviruses revealed full cell cycle reprogramming in 15% of the cardiomyocyte population at 48 hours after infection with 4F, which was associated mainly with sarcomere disassembly and metabolic reprogramming (n=3/time point/group). Transient overexpression of 4F, specifically in cardiomyocytes, was achieved using a polycistronic nonintegrating lentivirus (NIL) encoding 4F; each is driven by a TNNT2 (cardiac troponin T isoform 2) promoter (TNNT2-4Fpolycistronic-NIL). TNNT2-4Fpolycistronic-NIL or control virus was injected intramyocardially 1 week after myocardial infarction in rats (n=10/group) or pigs (n=6-7/group). Four weeks after injection, TNNT2-4Fpolycistronic-NIL-treated animals showed significant improvement in left ventricular ejection fraction and scar size compared with the control virus-treated animals. At 4 months after treatment, rats that received TNNT2-4Fpolycistronic-NIL still showed a sustained improvement in cardiac function and no obvious development of cardiac arrhythmias or systemic tumorigenesis (n=10/group). CONCLUSIONS: This study provides mechanistic insights into the process of forced cardiomyocyte proliferation and advances the clinical feasibility of this approach by minimizing the oncogenic potential of the cell cycle factors owing to the use of a novel transient and cardiomyocyte-specific viral construct.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Abouleisa, Salama, Ou, et al. Transient Cell Cycle Induction in Cardiomyocytes to Treat Subacute Ischemic Heart Failure. Circulation. 2022. PMID: 35061545. doi:10.1161/CIRCULATIONAHA.121.057641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。